Drug Database
CL

clotrimazole + betamethasone (Flotiran / Lotrisone / Lotricomb)

✓ Approved

Merck & Co. · NR3C1 · 小分子

什么是 clotrimazole + betamethasone?

clotrimazole + betamethasone 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名Flotiran, Lotrisone, Lotricomb
公司Merck & Co.
药物类别小分子
分子靶点NR3C1,
给药途径Unknown
状态Approved

作用机制

分子靶点

clotrimazole + betamethasone 作用于 2 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
sterol demethylase, Candida albicans (ERG11)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

clotrimazole + betamethasone 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsWound infection fungal✓ Approved

相关研究文献

PubMedPain physician2026-08-04

Safety and Effectiveness of Different Approaches for Epidural Steroid Injections in Lumbar Spinal Stenosis: A Systematic Review and Meta-Analysis.

Wilderman Igor I, Sarzetto Francesca F, Didari Tina T, Manor Rotem Frish RF et al.

Lumbar canal stenosis is a common degenerative disorder that causes pain and functional alterations. Epidural steroid injections (ESIs) are often used to treat the symptoms of this condition; however, treatment protocols can vary significantly, and no standardized practice for the management of lumbar canal stenosis has been established. To identify the optimal method of administration for maximizing the effectiveness and duration of pain relief and functionality improvements provided by ESIs. Systematic review and meta-analysis. We searched PubMed, Google Scholar, ScienceDirect, CINAHL, EMBASE, and OVID for clinical trials published from January 2000 to December 2025 that examined the effectiveness of different ESI protocols to ameliorate pain and functionality in spinal stenosis patients. The search terms included ("lumbar spinal stenosis" OR "lumbar canal stenosis" or "lumbar foraminal stenosis") AND "epidural steroid/corticosteroid injection(s)" AND ("interlaminar" OR "caudal" OR "transforaminal" OR "route"). Studies that met exclusion criteria were those that did not use human patients, that were not focused on lumbar stenosis, that had no consistent protocol, or did not express their outcomes as decreases in pain intensity. The risk of bias was assessed with the Cochrane RoB2 tool. We conducted a meta-analysis on the data from individual groups extracted from different studies, including sub-group and meta-regression analyses, to identify variables with significant effects. In total, 33 groups (comprising 1,350 patients) were extracted from 24 studies, with results from one week to 12 months after the injection. Most studies reported significant pain relief up to 3 months from the injections, and some reported that such pain relief persisted even after a year. Of all the factors that influenced the results, the type of steroid used had the greatest effect, with betamethasone providing the greatest and more prolonged relief. Triamcinolone and methylprednisolone offered similar initial levels of pain relief, though it decreased more rapidly, whereas dexamethasone showed the lowest level of benefits. Moreover, the pain relief effect was significantly weaker in patients with severe stenosis, and functionality improvements were also limited in patients with moderate/severe stenosis. In contrast, route of administration (transforaminal, interlaminar, or caudal), dose size, and other parameters showed no significant differences. Most groups included in the analysis were small, with 22 of the 33 (66.7%) having fewer than 50 patients, and only one group including more than 100. Furthermore, the results overall were significantly heterogeneous, and the follow-up times varied, meaning that some subgroups had only one result or none whatsoever at certain time points and limiting the subgroup analysis. ESIs are an effective treatment for the pain caused by spinal stenosis; betamethasone, even at a low dose, appears to provide the greatest benefits, whereas dexamethasone seems the least effective. Patients with mild or moderate stenosis are more likely to experience positive results from ESIs, and the administration route can be chosen depending on the patient's status, offering similar effects. The transforaminal route is likely more beneficial in single-level stenosis, while interlaminar (at the level of maximal stenosis or one caudad) and caudal injections are more appropriate for multilevel pathologies.

PMID 42550520
阅读全文 →
PubMedMedical mycology case reports2026-08-02

Canine dermatophytosis due to Arthroderma uncinatum: case report and diagnostic considerations.

Samarelli Rossella R, Otranto Domenico D, Miglianti Mara M, Bezerra-Santos Marcos Antonio MA et al.

This report describes a molecularly confirmed case of canine dermatophytosis caused by Arthroderma uncinatum in an 11-month-old English Setter from Southern Italy. The dog presented with two alopecic, erythematous, scaling lesions on the metacarpal and metatarsal regions. While routine microscopic examinations were inconclusive, dermatophyte culture yielded a fungal isolate identified as A. uncinatum by ITS sequencing. Topical 1% clotrimazole administered for three weeks resulted in complete clinical and mycological cure. This case documents an uncommon infection by a geophilic dermatophyte and expands veterinary knowledge of A. uncinatum-associated canine disease.

PMID 42541109
阅读全文 →
PubMedJournal of medical ultrasonics (2001)2026-08-02

Ultrasound-guided cervical selective nerve root block with or without steroid.

Iwata Shuhei S, Kojima Atsushi A, Hatakeyama Kenji K, Ohtori Seiji S

To compare short-term pain trajectories after ultrasound (US)-guided cervical selective nerve root block (SNRB) using a steroid-containing injectate versus a no-steroid injectate in patients with cervical radicular pain. This single-center prospective comparative study used time-period-based allocation of injectate. Consecutive patients undergoing a first-time US-guided cervical SNRB between 2021 and 2024 were reviewed. The steroid group received 1% lidocaine 1 mL + normal saline 2 mL + betamethasone 4 mg (1 mL). The no-steroid group received 1% lidocaine 1 mL + normal saline 3 mL. Pain intensity was assessed using the numerical rating scale (NRS; 0-10) at baseline, 15 min, day 1, day 2, and day 14. The primary analysis used a mixed model for repeated measures (MMRM) with group, time, and group-by-time interaction; the primary estimand was the between-group difference in change from baseline to day 14. Secondary analyses estimated between-group differences at each post-baseline time point. Safety outcomes included procedure-related complications and 3-month clinical course. Of 97 screened patients, 70 were analyzed (steroid: n = 43, no-steroid: n = 27). Baseline NRS was similar (6.98 ± 2.38 vs 6.93 ± 2.29). The group-by-time interaction was significant (p = 0.0036). At day 14, the steroid group showed greater improvement than the no-steroid group (MMRM between-group difference in change: - 1.55; p = 0.0077). Model-based differences favored steroid from 15 min through day 14. No procedure-related complications occurred; six patients underwent surgery during 3-month follow-up. In US-guided cervical SNRB, adding betamethasone was associated with superior short-term pain improvement without observed complications.

PMID 42541641
阅读全文 →
PubMedOrganic & biomolecular chemistry2026-07-31

From alpha to beta: a two-step strategy for stereoinversion of C16 glucocorticoids.

Wei Jianhai J, Zhang Yajiao Y, Tao Yuan Y, He Hangli H et al.

C16-Methylcorticoids are important anti-inflammatory agents whose activity depends on the C16 methyl configuration. However, access to C16β analogues remains challenging. Herein, we report the first concise two-step stereoinversion of C16α-methylcorticoids to C16β diastereomers through C17 hydroxyl elimination followed by Mn-catalyzed Mukaiyama hydration. Betamethasone, beclomethasone, clobetasol, clobetamethasone, and difluorolaxone were obtained in useful yields with high diastereoselectivities (19 : 1 to >99 : 1 dr).

PMID 42535937
阅读全文 →
PubMedPloS one2026-07-31

Isolation and characterization of Candida metapsilosis from foci of chronic pododermatitis in captive steppe eagles in Kazakhstan.

Kukhar Elena E, Bailina Gulshat G, Nessipbayeva Aziza A, Sattarova Rano R et al.

Pododermatitis (bumblefoot) is a chronic, debilitating disease of the plantar surface of the foot that affects birds of prey kept in captivity worldwide. Although bacterial pathogens, especially Staphylococcus aureus, are most commonly considered as causative agents, the contribution of opportunistic yeasts to chronic, non-healing footpad lesions remains poorly characterized. Keratinophilic yeasts may sustain the disease process by degrading keratin in superficial tissues, impairing wound healing and, owing to their thermotolerance and minimal nutritional requirements, persisting in the environment of the bird's enclosure. In this study, three captive steppe eagles (Aquila nipalensis) from a single aviary in Kazakhstan, all presenting with chronic pododermatitis unresponsive to antibacterial treatment, were investigated by integrated mycological, biochemical and molecular approaches. The yeast isolates were recovered from the deep footpad lesions and identified to species level by sequencing of the ITS1-5.8S-ITS2 rDNA region. All these isolates were assigned to Candida metapsilosis, and phylogenetic analysis confirmed their close clustering with reference C. metapsilosis sequences. Phenotypic characterization showed that all isolates were thermotolerant (growth at 8-37 °C), expressed strong urease and keratinolytic activity (the latter confirmed in vitro by the hair perforation test), high saccharolytic activity and selective, weak proteolytic activity. Disk diffusion screening showed susceptibility to azoles (ketoconazole, clotrimazole, fluconazole) and reduced susceptibility to polyenes (nystatin, amphotericin B). To our knowledge, this is the first report of C. metapsilosis isolated from chronic pododermatitis lesions in captive steppe eagles. Combined with the documented in vitro virulence-associated traits and the resolution of the lesions following targeted antifungal therapy, our findings support a contributory etiological role of C. metapsilosis as an opportunistic pathogen in raptor pododermatitis in immunocompromised birds maintained under suboptimal husbandry. Mycological work-up, including molecular identification, is therefore warranted in cases of chronic, non-resolving pododermatitis in captive birds of prey.

PMID 42536651
阅读全文 →
PubMedFrontiers in bioscience (Landmark edition)2026-07-30

Betamethasone Dipropionate Inhibits NLRP3 Inflammasome Activation by Suppressing Pro-IL-1β Expression.

Huang Weichen W, Xie Shoufeng S, Rong Xinyu X, Liu Yongzhi Y et al.

The NOD-like receptor Family, pyrin domain-containing 3 protein (NLRP3) inflammasome is a macromolecular complex critical for inflammatory responses. Its excessive activation or improper regulation is intimately associated with the development of various inflammatory diseases. However, currently available drugs directly targeting the NLRP3 inflammasome are limited. In preliminary analyses, detecting the level of secreted interleukin-1 beta (IL-1β) revealed that betamethasone-17,21-dipropionate (also known as betamethasone dipropionate, BD), a clinically used glucocorticoid, potentially inhibits NLRP3 inflammasome activation. In vitro, the role and preliminary mechanism of BD in inhibiting the activation of NLRP3 inflammasome were investigated in THP-1-differentiated macrophages and bone marrow-derived macrophages (BMDMs) using enzyme-linked immunosorbent assay (ELISA), Cell Counting Kit-8 (CCK-8), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blotting (WB). The preliminary effects of BD on the assembly of NLRP3 inflammasome were assessed in HEK293T cells overexpressing NLRP3/ASC/caspase-1/NEK7 through drug affinity responsive target stability (DARTS) and co-immunoprecipitation (Co-IP) approaches. In vivo, the effect of BD on LPS-induced systemic inflammation was assessed by measuring serum concentrations of IL-1β and TNF-α via ELISA, and by recording mouse survival rates and body weights. BD significantly inhibited NLRP3 inflammasome activation by suppressing pro-IL-1β expression in vitro. Mechanistic studies showed that it decreased pro-IL-1β expression by suppressing NF-κB signaling. In vivo, BD downregulated the serum concentrations of IL-1β and TNF-α, and increase the survival rate of mice using the LPS-induced systemic inflammation model. Collectively, our data verify that BD inhibits NLRP3 inflammasome activation by suppressing pro-IL-1β expression. These findings suggest that BD may be a potential therapeutic approach for inflammatory diseases. However, further studies are needed to elucidate its precise role and specific mechanism in clinical practice.

PMID 42530265
阅读全文 →

注册免费账户还可查看另外 9031 篇文献

免费注册查看全部文献 →

了解更多clotrimazole + betamethasone